Clinical correlates of anhedonia in patients with Parkinson's disease. 2013

Kiyohiro Matsui, and Hisao Tachibana, and Toshiyuki Yamanishi, and Miyako Oguru, and Kazuo Toda, and Bungo Okuda, and Nobuyuki Oka
Department of Internal Medicine, Hyogo College of Medicine, Nishinomiya, Japan.

OBJECTIVE To investigate the prevalence and clinical correlates of anhedonia in patients with Parkinson's disease (PD) and to also examine the relationship between anhedonia and the QOL. METHODS One hundred and seventeen patients with PD completed the Snaith-Hamilton Pleasure Scale (SHAPS), the State-Trait Anxiety Inventory (STAI), the Beck Depression Inventory Second Edition (BDI-II), Starkstein's Apathy Scale (AS) and a quality of life (QOL) battery. Hoehn and Yahr (HY) staging, the Unified Parkinson's Disease Rating Scale (UPDRS) and the Mini-Mental State Examination (MMSE) were administered on the same day. RESULTS Anhedonia (SHAPS score≄3) was diagnosed in 15% of the patients. The SHAPS score was found to be significantly correlated with the HY stage and the UPDRS (I, IVB, IVC, total), BDI-II, AS and STAI (State, Trait) scores. A multivariate analysis revealed that the BDI-II and STAI (Trait) scores significantly influenced the SHAPS scores. The SHAPS scores were found to be negatively correlated with the QOL. CONCLUSIONS These findings indicate that anhedonia is associated with depression and anxiety. In addition, recognizing anhedonia in patients with PD is important since it may have a negative effect on the QOL.

UI MeSH Term Description Entries
D007980 Levodopa The naturally occurring form of DIHYDROXYPHENYLALANINE and the immediate precursor of DOPAMINE. Unlike dopamine itself, it can be taken orally and crosses the blood-brain barrier. It is rapidly taken up by dopaminergic neurons and converted to DOPAMINE. It is used for the treatment of PARKINSONIAN DISORDERS and is usually given with agents that inhibit its conversion to dopamine outside of the central nervous system. L-Dopa,3-Hydroxy-L-tyrosine,Dopaflex,Dopar,L-3,4-Dihydroxyphenylalanine,Larodopa,Levopa,3 Hydroxy L tyrosine,L 3,4 Dihydroxyphenylalanine,L Dopa
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009483 Neuropsychological Tests Tests designed to assess neurological function associated with certain behaviors. They are used in diagnosing brain dysfunction or damage and central nervous system disorders or injury. Aphasia Tests,Cognitive Test,Cognitive Testing,Cognitive Tests,Memory for Designs Test,Neuropsychological Testing,AX-CPT,Behavioral Assessment of Dysexecutive Syndrome,CANTAB,Cambridge Neuropsychological Test Automated Battery,Clock Test,Cognitive Function Scanner,Continuous Performance Task,Controlled Oral Word Association Test,Delis-Kaplan Executive Function System,Developmental Neuropsychological Assessment,Hooper Visual Organization Test,NEPSY,Neuropsychologic Tests,Neuropsychological Test,Paced Auditory Serial Addition Test,Repeatable Battery for the Assessment of Neuropsychological Status,Rey-Osterrieth Complex Figure,Symbol Digit Modalities Test,Test of Everyday Attention,Test, Neuropsychological,Tests, Neuropsychological,Tower of London Test,Neuropsychologic Test,Test, Cognitive,Testing, Cognitive,Testing, Neuropsychological,Tests, Cognitive
D010300 Parkinson Disease A progressive, degenerative neurologic disease characterized by a TREMOR that is maximal at rest, retropulsion (i.e. a tendency to fall backwards), rigidity, stooped posture, slowness of voluntary movements, and a masklike facial expression. Pathologic features include loss of melanin containing neurons in the substantia nigra and other pigmented nuclei of the brainstem. LEWY BODIES are present in the substantia nigra and locus coeruleus but may also be found in a related condition (LEWY BODY DISEASE, DIFFUSE) characterized by dementia in combination with varying degrees of parkinsonism. (Adams et al., Principles of Neurology, 6th ed, p1059, pp1067-75) Idiopathic Parkinson Disease,Lewy Body Parkinson Disease,Paralysis Agitans,Primary Parkinsonism,Idiopathic Parkinson's Disease,Lewy Body Parkinson's Disease,Parkinson Disease, Idiopathic,Parkinson's Disease,Parkinson's Disease, Idiopathic,Parkinson's Disease, Lewy Body,Parkinsonism, Primary
D011569 Psychiatric Status Rating Scales Standardized procedures utilizing rating scales or interview schedules carried out by health personnel for evaluating the degree of mental illness. Factor Construct Rating Scales (FCRS),Katz Adjustment Scales,Lorr's Inpatient Multidimensional Psychiatric Rating Scale,Wittenborn Scales,Edinburgh Postnatal Depression Scale,Mini International Neuropsychiatric Interview
D011788 Quality of Life A generic concept reflecting concern with the modification and enhancement of life attributes, e.g., physical, political, moral, social environment as well as health and disease. HRQOL,Health-Related Quality Of Life,Life Quality,Health Related Quality Of Life
D003863 Depression Depressive states usually of moderate intensity in contrast with MAJOR DEPRESSIVE DISORDER present in neurotic and psychotic disorders. Depressive Symptoms,Emotional Depression,Depression, Emotional,Depressive Symptom,Symptom, Depressive
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

Kiyohiro Matsui, and Hisao Tachibana, and Toshiyuki Yamanishi, and Miyako Oguru, and Kazuo Toda, and Bungo Okuda, and Nobuyuki Oka
July 2011, Geriatrics & gerontology international,
Kiyohiro Matsui, and Hisao Tachibana, and Toshiyuki Yamanishi, and Miyako Oguru, and Kazuo Toda, and Bungo Okuda, and Nobuyuki Oka
January 2017, Journal of the neurological sciences,
Kiyohiro Matsui, and Hisao Tachibana, and Toshiyuki Yamanishi, and Miyako Oguru, and Kazuo Toda, and Bungo Okuda, and Nobuyuki Oka
September 2003, Journal of neurology, neurosurgery, and psychiatry,
Kiyohiro Matsui, and Hisao Tachibana, and Toshiyuki Yamanishi, and Miyako Oguru, and Kazuo Toda, and Bungo Okuda, and Nobuyuki Oka
April 2018, Parkinsonism & related disorders,
Kiyohiro Matsui, and Hisao Tachibana, and Toshiyuki Yamanishi, and Miyako Oguru, and Kazuo Toda, and Bungo Okuda, and Nobuyuki Oka
March 1997, Experimental neurology,
Kiyohiro Matsui, and Hisao Tachibana, and Toshiyuki Yamanishi, and Miyako Oguru, and Kazuo Toda, and Bungo Okuda, and Nobuyuki Oka
January 2012, The Journal of neuropsychiatry and clinical neurosciences,
Kiyohiro Matsui, and Hisao Tachibana, and Toshiyuki Yamanishi, and Miyako Oguru, and Kazuo Toda, and Bungo Okuda, and Nobuyuki Oka
January 2011, ISRN neurology,
Kiyohiro Matsui, and Hisao Tachibana, and Toshiyuki Yamanishi, and Miyako Oguru, and Kazuo Toda, and Bungo Okuda, and Nobuyuki Oka
January 2005, Rinsho shinkeigaku = Clinical neurology,
Kiyohiro Matsui, and Hisao Tachibana, and Toshiyuki Yamanishi, and Miyako Oguru, and Kazuo Toda, and Bungo Okuda, and Nobuyuki Oka
November 2002, Brain : a journal of neurology,
Kiyohiro Matsui, and Hisao Tachibana, and Toshiyuki Yamanishi, and Miyako Oguru, and Kazuo Toda, and Bungo Okuda, and Nobuyuki Oka
January 2020, Parkinson's disease,
Copied contents to your clipboard!